Previous 10 | Next 10 |
Do you ever get the feeling the stock market isn't reading the same news that you are? Compass Pathways (NASDAQ: CMPS) shareholders know that feeling. The clinical-stage drugmaker recently told investors its psilocybin-based treatment hit high marks in a closely watched depression s...
Shares of the psychedelic healthcare company Compass Pathways (NASDAQ: CMPS) sank by nearly 30% through Thursday's closing bell this week, according to data from S&P Global Market Intelligence . Last Tuesday, the company reported its 2021 third-quarter earnings results ahead...
Compass Pathways (NASDAQ: CMPS) is not your typical healthcare company. The London-based clinical-stage biopharma is developing therapies for various forms of depression that center around psilocybin, the main psychoactive compound of hallucinogenic mushrooms. This compound also hap...
Post-traumatic stress disorder (PTSDF) affects millions of people. In fact, according to The Recovery Village, about eight million Americans currently deal with PTSD. In addition, about 20% of people who experience a traumatic event will develop PTSD at some point. Unfortunately, according ...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q3 2021 Earnings Call Nov 09, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript
The head of COMPASS Pathways (NASDAQ:CMPS) contended Tuesday that investors should keep in mind the positive results displayed in a recent clinical trial of its experimental psychedelics-based treatment for depression. His comments came as safety concerns stemming from the study sparked a dou...
Compass Pathways (NASDAQ: CMPS) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40.65 on Tuesday and fell as low as $30.52 in midday trading. The stock, which is down more than 6....
Gainers: Dover Motorsports (NYSE:DVD) +57%. TDH Holdings (NASDAQ:PETZ) +40%. New Relic (NYSE:NEWR) +35%. Roblox (NYSE:RBLX) +32%. Guaranty Federal Bancshares (NASDAQ:GFED) +31%. Bit Brother (NASDAQ:BTB) +29%. Altimeter Growth (NASDAQ:AGC) +26%. Altimeter Growth (NASDAQ:AGCUU) +26%. Katapult (...
In the early hours, Cybin (NYSE:CYBN) was a notable gainer among the developers of psychedelic-based therapies after Oppenheimer increased its price target to $10 from $7 per share in the wake of Phase 2 data shared by COMPASS Pathways (CMPS -22.6%) for COMP360 psilocybin therapy. The an...
Investors have not reacted favorably to phase 2b results of COMPASS Pathways' (CMPS -22.1%) psilocybin treatment for treatment-resistant depression, bringing shares down. Top-line data showed that based on the Montgomery-Asburg Depression Rating Scale ("MADRS"), those who received 25mg of the...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...